Pfizer Inc. (NYSE:PFE) Shares Acquired by Davidson Trust Co.

Davidson Trust Co. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 17.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,604 shares of the biopharmaceutical company’s stock after acquiring an additional 6,948 shares during the quarter. Davidson Trust Co.’s holdings in Pfizer were worth $1,181,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in PFE. Beam Wealth Advisors Inc. grew its position in Pfizer by 1.5% during the 4th quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock worth $728,000 after purchasing an additional 401 shares during the period. Providence Capital Advisors LLC boosted its stake in shares of Pfizer by 0.4% in the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock worth $3,034,000 after buying an additional 409 shares during the last quarter. Donaldson Capital Management LLC raised its position in Pfizer by 1.2% during the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after acquiring an additional 410 shares in the last quarter. William B. Walkup & Associates Inc. lifted its holdings in Pfizer by 1.2% in the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock valued at $1,044,000 after acquiring an additional 454 shares during the period. Finally, Balboa Wealth Partners boosted its position in Pfizer by 1.6% in the 4th quarter. Balboa Wealth Partners now owns 30,678 shares of the biopharmaceutical company’s stock worth $814,000 after purchasing an additional 480 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on PFE. Jefferies Financial Group lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday, May 21st. Bank of America lifted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Berenberg Bank lowered their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Wolfe Research raised their target price on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research report on Wednesday, April 30th. Finally, BMO Capital Markets cut their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.55.

Pfizer Trading Up 0.5%

Shares of PFE opened at $25.45 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The stock has a market cap of $144.66 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The firm’s fifty day moving average is $23.67 and its two-hundred day moving average is $24.84. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.82 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.